Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

By M. Callery, Kenneth J. Chang, E. Fishman, M. Talamonti, L. William Traverso, D. Linehan. Annals of Surgical Oncology, 2009

874 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “The additional use of staging laparoscopy to exclude peritoneal metastasis in resectable or borderline resectable patients has been suggested by some authors, but it is not generally accepted [14] [IV, C].”
Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial (2018, methodology): “Recently, a multicenter prospective study based on standardization of the radiologic criteria was performed.(15,27) In this study, a standardized radiologic reporting system for tumor invasion, including the extent and degree, was used.”
A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer (2016, methodology): “Finally, no study reported standard pretreatment staging laparoscopy, as recommended by a consensus statement.(6) Staging laparoscopy has been demonstrated to upstage patients to metastatic disease in up to a third of patients in two studies.”